Join BJS Academy
BJS Academy>Randomized clinical ...>Immediate surgery co...
Normal View Dyslexic View

Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.

26 April 2023
Randomized clinical trials HPB
Ghaneh P, Palmer D, Cicconi S, Jackson R, Halloran CM, Rawcliffe C et al, for the European Study Group for Pancreatic Cancer.

Lancet Gastro Hepatol 2023; 8: 157-168.

This study included 83 evaluable patients from 478 screened. Neoadjuvant treatment did not reduce the resection rate. Neoadjuvant treatment improved 1-year disease-free survival in both groups combined: 59 versus 39% for immediate surgery (hazard ratio 0.53, 95 per cent confidence interval 0.28 to 0.98, P=0.016.

Comment: The evidence for neoadjuvant chemotherapy is accumulating, but the number of suitable patients may be small.

BJS Foundation Limited
BJS Academy
0000-0000
BJS Foundation Limited
London, UK
rct117
Randomized clinical trials
Randomized clinical trials
HPB
Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.
Ghaneh P, Palmer D, Cicconi S, Jackson R, Halloran CM, Rawcliffe C et al, for the European Study Group for Pancreatic Cancer.
26042023
Lancet Gastro Hepatol 2023; 8: 157-168.
This study included 83 evaluable patients from 478 screened. Neoadjuvant treatment did not reduce the resection rate. Neoadjuvant treatment improved 1-year disease-free survival in both groups combined: 59 versus 39% for immediate surgery (hazard ratio 0.53, 95 per cent confidence interval 0.28 to 0.98, P=0.016.
Comment: The evidence for neoadjuvant chemotherapy is accumulating, but the number of suitable patients may be small.
Published on: 26 April 2023
Article ID: rct117

Related articles

Temporary portocaval shunt provides superior intraoperative hemodynamics and reduces blood loss and duration of surgery in live donor liver transplantation. A randomized controlled trial.

Kumar M, Patil NS, Mohapatra N, Sindwani G, Dhingra U, Yadav A et al.
Ann Surg 2024; 279: 932-944.

16 August 2024

Upfront endoscopic necrosectomy or step-up endoscopic approach for infected necrotising pancreatitis (DESTIN): a single-blinded, multicentre, randomised trial.

Bang JY, Lakhtakia S, Thakkar S, Buxbaum JL, Waxman I, Sutton B et al, on behalf of the United States Pancreatic Disease Study Group.

16 August 2024

Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.

Labori KJ, Bratlie SO, Andersson B, Angelsen J-H, Biorserud C, Bjornsson B et al, for the Nordic Pancreatic Cancer Trial-1 study group.

30 August 2024
Home
  • Normal view
  • Dyslexic view
Info
Copied!